IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Pharmaceuticals

Market Closed - OTC Markets 03:03:06 2024-04-19 pm EDT 5-day change 1st Jan Change
0.165 USD -2.94% Intraday chart for IntelGenx Technologies Corp. -10.86% +19.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences MT
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million MT
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding CI
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm MT
IntelGenx Technologies Corp. announced that it has received CAD 1.01451 million in funding from ATAI Life Sciences AG CI
IntelGenx Technologies Corp. Announces Changes to its Board of Directors CI
IntelGenx Announcing Shareholder Approval of Financing Transactions MT
IntelGenx Brief: Announcing Shareholder Approval of Financing Transactions MT
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease MT
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease CI
Transcript : IntelGenx Technologies Corp., Q3 2023 Earnings Call, Nov 09, 2023
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IntelGenx Announced Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray MT
IntelGenx Brief: Announciing Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray MT
Chart IntelGenx Technologies Corp.
More charts
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.17
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. IGXT Stock
  4. News IntelGenx Technologies Corp.
  5. IntelGenx Technologies : Raises US$2.1 Million From Placement of Convertible Debentures